[Podcast] The Conflict Between QALYs for Drug Value and Patient Advocacy Groups
In the latest episode of the Relentless Health Value podcast, Stacey Richter interviews Memorial Sloan Kettering’s Anna Kaltenboeck about how [...]
Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States
Cost-effectiveness analysis is an important tool for informing treatment coverage and pricing decisions. However, there is no consensus on whether [...]
New Study Examines Perspective and Costing in Cost-Effectiveness Analysis
A recent study examined perspective and costing approaches used in cost-effectiveness analyses (CEAs) and the distribution of reported incremental cost-effectiveness [...]
Value of a QALY for France
Until now, no cost-effectiveness threshold (CET) has been officially proposed in France to qualify incremental cost-effectiveness ratios (ICERs). To address [...]
Tufts Analyzes Cost-Effectiveness Analysis for 1974-2018
Kim et. al. of Tufts Medical Center published an examination in the journal Pharmacoeconomics assessing CEA and Global Health CEA [...]
Column: Coronavirus Pulls Back Curtain on Health Rationing
In a recent guest column published in the Orlando Sentinel, Sue Peschin, president and CEO of the Alliance for Aging [...]
More on Report from Pioneer Institute on QALY
Pharmaphorum in a recent report highlights a new analysis by the Pioneer Institute that suggests the Institute for Clinical and [...]
Analysis Suggests ICER’s QALY Approach Violates ADA
A new analysis by the Pioneer Institute, "The Legality of QALY under the ADA," suggests that the Institute for Clinical [...]
Denmark Adopting QALY System for Hospital Drugs
Denmark is shifting to a new evaluation system for hospital drugs based on the quality-adjusted life year (QALY), according to [...]
New Framework Introduces New Metric in Cost-Effectiveness Analysis
A recent article published in Value in Health proposes a new framework for valuing health outcomes in cost-effectiveness analyses and [...]
Report: Denmark Adopting QALY in Cost-Effectiveness Assessments
Beginning in October, the Danish Medicines Council will use the quality-adjusted life year (QALY) metric in its cost-effectiveness assessments, The [...]
Article: Don’t Let QALY Restrict Life-Saving Drugs
Gunnar Esiason, an MBA/MPH candidate at the Dartmouth Tuck School of Business, in a recent article published on The Hill [...]
CVS Caremark’s foray into cost-effectiveness analysis raises questions about the future of prescription medicines in America
Written By: Americans spend more on prescription drugs than anyone else in the world. In a move to address this, [...]
